CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) Short Interest Update

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) was the recipient of a significant decrease in short interest during the month of August. As of August 31st, there was short interest totaling 2,193 shares, a decrease of 82.6% from the August 15th total of 12,595 shares. Currently, 0.2% of the company’s stock are short sold. Based on an average daily volume of 10,393 shares, the days-to-cover ratio is presently 0.2 days.

Hedge Funds Weigh In On CNS Pharmaceuticals

Several institutional investors have recently modified their holdings of CNSP. Armistice Capital LLC bought a new position in shares of CNS Pharmaceuticals during the 2nd quarter valued at $335,000. ADAR1 Capital Management LLC bought a new stake in CNS Pharmaceuticals in the second quarter worth $335,000. Ikarian Capital LLC purchased a new stake in CNS Pharmaceuticals during the fourth quarter valued at about $241,000. Stonepine Capital Management LLC bought a new position in shares of CNS Pharmaceuticals during the second quarter valued at about $198,719. Finally, Boothbay Fund Management LLC bought a new position in shares of CNS Pharmaceuticals during the fourth quarter valued at about $71,000. 14.02% of the stock is currently owned by institutional investors.

CNS Pharmaceuticals Price Performance

Shares of NASDAQ CNSP traded up $0.09 during mid-day trading on Friday, reaching $5.84. 18,542 shares of the company’s stock were exchanged, compared to its average volume of 8,220. The firm has a market capitalization of $8.53 million, a price-to-earnings ratio of -0.25 and a beta of 3.06. CNS Pharmaceuticals has a 52 week low of $1.90 and a 52 week high of $10.59. The firm has a 50-day moving average price of $5.44 and a two-hundred day moving average price of $4.36.

CNS Pharmaceuticals (NASDAQ:CNSP) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.14).

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of CNS Pharmaceuticals in a report on Friday, July 17th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, CNS Pharmaceuticals currently has an average rating of “Sell”.

CNS Pharmaceuticals Company Profile

CNS Pharmaceuticals, Inc, headquartered in Houston, Texas, is a clinical-stage biopharmaceutical company focused on developing therapies for aggressive central nervous system tumors. The company’s lead candidate, berubicin, is an anthracycline derivative engineered to cross the blood-brain barrier for the treatment of glioblastoma multiforme and other brain cancers. In addition to berubicin, CNS Pharmaceuticals is advancing WP1066, an immunotherapy agent designed to inhibit the STAT3 signaling pathway and enhance anti-tumor immune activity in the tumor microenvironment.

Berubicin has completed a Phase 1 clinical trial in patients with recurrent glioblastoma, where it demonstrated proof-of-concept signals, and is currently in Phase 2 development.